Skip to main content
SpringerLink
Log in

Upadacitinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–24.

    Article  CAS  Google Scholar 

  2. AbbVie. AbbVie receives FDA approval of RINVOQTM (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis [media release]. 16 Aug 2019. http://www.abbvie.com.

  3. AbbVie. RINVOQ™ (upadacitinib) extended-release tablets, for oral use: US prescribing information. 2019. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 2019.

  4. Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.

    Article  Google Scholar 

  5. Sornasse T, Sokolove J, McInnes I. Treatment with upadacitinib results in the normalization of key pathobiologic pathways in patients with rheumatoid arthritis: Biomarker results from the phase 3 selectnext and select-beyond studies [abstract no. THU0181]. Ann Rheum Dis. 2019;78(Suppl. 2):365–6.

    Google Scholar 

  6. Nurmohamed M, Zhang Y, Lin J, et al. Changes in C-reactive protein and lipid levels in patients with rheumatoid arthritis treated with ABT-494 a selective JAK-1 inhibitor [abstract no. THU0203]. Ann Rheum Dis. 2017;76(Suppl. 2):280.

    Google Scholar 

  7. Charles-Schoeman C, Sornasse T, Sokolove J. Treatment with upadacitinib is associated with improvements in reverse cholesterol transport in patients with rheumatoid arthritis: correlation with changes in inflammation and HDL levels [abstract no. THU0166]. Ann Rheum Dis. 2019;78(Suppl. 2):356–7.

    Google Scholar 

  8. Song T, Pavel AB, Peng X, et al. Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates [abstract no. 1024]. J Investig Dermatol. 2019;139(5 Suppl.):S177.

    Article  Google Scholar 

  9. Beck LA, Silverberg JI, Grebe K, et al. Eosinophil count and serum immunoglobulin E levels in atopic dermatitis: analysis of upadacitinib phase 2 study findings [abstract no. 376]. J Allergy Clin Immunol. 2019;143(2 Suppl.):AB125.

    Article  Google Scholar 

  10. Aguilar D, Planell N, Panes J, et al. Upadacitinib-induced endoscopic improvement is associated with modulation of pathways involved in Crohn’s disease pathogenesis [abstract no. P843]. J Crohns Colitis. 2018;12(Suppl. 1):S542–3.

    Article  Google Scholar 

  11. Mohamed MF, Zeng J, Jiang P, et al. Use of early clinical trial data to support thorough QT study waiver for upadacitinib and utility of food effect to demonstrate ECG assay sensitivity. Clin Pharmacol Ther. 2018;103(5):836–42.

    Article  Google Scholar 

  12. Klunder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57(8):977–88.

    Article  Google Scholar 

  13. Klunder B, Mittapalli RK, Mohamed MF, et al. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019;58(8):1045–58.

    Article  CAS  Google Scholar 

  14. Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–58.

    Article  CAS  Google Scholar 

  15. Mohamed MF, Zeng J, Marroum PJ, et al. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019;8(2):208–16.

    Article  CAS  Google Scholar 

  16. Mohamed MF, Jungerwirth S, Asatryan A, et al. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242–8.

    Article  CAS  Google Scholar 

  17. Mohamed MF, Trueman S, Feng T, et al. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019;59(6):856–62.

    Article  CAS  Google Scholar 

  18. Trueman S, Mohamed MF, Feng T, et al. Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019;59(9):1188–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Mohamed MF, Feng T, Enejosa JV, et al. Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified Cooperstown 5 + 1 cocktail. J Clin Pharmacol. 2019. https://doi.org/10.1002/jcph.1496.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12.

    Article  CAS  Google Scholar 

  21. Burmester GR, Van Den Bosch F, Bessette L, et al. Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to CSDMARDS: results at 60 weeks from the select-next study [abstract no. FRI0132]. Ann Rheum Dis. 2019;78(Suppl. 2):735–6.

    Google Scholar 

  22. Genovese MC, Combe B, Hall S, et al. Upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological DMARDS: results at 60 weeks from the select-beyond study [abstract no. THU0172]. Ann Rheum Dis. 2019;78(Suppl. 2):360–1.

    Google Scholar 

  23. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–11.

    Article  Google Scholar 

  24. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019. https://doi.org/10.1002/art.41032.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019. https://doi.org/10.1136/annrheumdis-2019-215764.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Van Vollenhoven R, Takeuchi T, Pangan AL, et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naive patients with active rheumatoid arthritis [abstract no. 891]. Arthritis Rheumatol. 2018;70(Suppl 9):990–2.

    Google Scholar 

  27. Van Vollenhoven R, Takeuchi T, Pangan A, et al. Monotherapy with upadacitinib in MTX-naive patients with rheumatoid arthritis: results at 48 weeks from the select-early study [abstract no. THU0197]. Ann Rheum Dis. 2019;78(Suppl. 2):376–7.

    Google Scholar 

  28. Tanaka Y, Takeuchi T, Yamaoka K, et al. A phase 2b/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs [abstract no. SAT0257]. Ann Rheum Dis. 2018;77(Suppl 2):991–2.

    Google Scholar 

  29. Kremer JM, Emery P, Camp HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–77.

    Article  CAS  Google Scholar 

  30. Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–66.

    Article  CAS  Google Scholar 

  31. Genovese MC, Kremer J, Zhong S, et al. Long-term safety and efficacy of upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open label extension study [abstract no. SAT0236]. Ann Rheum Dis. 2018;77(Suppl 2):979.

    Google Scholar 

  32. Sandborn WJ, Feagan BG, Panes J, et al. Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn’s disease: results from Celest [abstract no. 874h]. Gastroenterology. 2017;152(5 Suppl 1):S1308–9.

    Article  Google Scholar 

  33. Panes J, Sandborn WJ, Loftus EV, et al. Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: results from the CELEST study [abstract no. 906]. Gastroenterology. 2018;154(6 Suppl 1):S-178–9.

    Google Scholar 

  34. De Bruin-Weller MS, Guttman-Yassky E, Forman SB, et al. Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase IIb randomized, placebo-controlled trial [abstract no. O19]. Br J Dermatol. 2018;179(1):e13.

    Article  Google Scholar 

  35. Reich K, Guttman-Yassky E, Beck LA, et al. Early response to upadacitinib in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial [abstract no. 0135]. Allergy Eur J Allergy Clin Immunol. 2018;73(Suppl. 105):76.

    Google Scholar 

  36. Sandborn WJ, Ghosh S, Panes J, et al. Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: data from the phase 2b study U-ACHIEVE [abstract no. OP195]. United Eur Gastroenterol. 2018;6(8 Suppl):A74–5.

    Google Scholar 

  37. Cohen SB, Van Vollenhoven R, Winthrop K, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program [abstract no. THU0167]. Ann Rheum Dis. 2019;78(Suppl 2):357.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sean Duggan & Susan J. Keam

Authors
  1. Sean Duggan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean Duggan.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan and Susan Keam are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

Additional information

Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.9932306.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duggan, S., Keam, S.J. Upadacitinib: First Approval. Drugs 79, 1819–1828 (2019). https://doi.org/10.1007/s40265-019-01211-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01211-z

Search

Navigation